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ABSTRACT
Acute lymphoblastic leukemia (ALL) is one of the most common cancers among 
children in the world, with almost 90% complete remission rate after the primary 
treatment. However, some patients are resistant to treatment and some relapse 
later. Moreover, existing treatments are toxic and induce life-long adverse effects. 
Potentially, it can be avoided if a more specific drug is used. Therefore, there is a 
need for new therapeutic targets and reliable validation of the developed drugs to 
avoid potential off-target effects. The family of serine-threonine polo-like kinases 
(Plk) is important for cell cycle. Among other family members, Polo-like kinase 1 
is a crucial regulator of mitosis, and it is particularly important for the proliferation 
of cancer cells This thesis aimed to improve understanding of Plk1 as a treatment 
target in pediatric leukemia. 
In Paper I we aimed to identify the potential off-target proteins of Plk1 small-
molecule inhibitors such as BI2536, volasertib and NMS-1286937. The drugs are 
already involved in the late-stage clinical trials and result in severe side-effects 
that may affect the survival of the patients. We used cellular thermal shift assay 
and thermal proteome profiling to identify the proteins that have a change in the 
thermal stability after treatment. We found that the BI2536 and volasertib bind to 
Prostaglandin reductase 2 (PTGR2), an enzyme that regulates prostaglandin E2 
metabolism and contributes to immune response. Also, we found that volasertib 
and NMS-1286937 affect the stability of a number of transcriptional coactiva-
tors, RNA splicing regulators, and proteins involved in the intracellular transport.
In Papers II and III we investigated the potential of Plk1 as a treatment target in 
primary cells from pediatric T-cell and B-cell ALL. We showed that Plk1 is highly 
expressed both in patient cells and T/B-cell ALL cell lines, compared to peripheral 
blood mononuclear cells (PBMCs) from healthy donors. Further we targeted pri-
mary patient cells with RNAi prodrugs – short interfering RiboNucleic Neutrals 
(siRNN). We showed that siRNNs entered leukemic cells and induced specific 
Plk1 mRNA knockdown followed by double-strand DNA breaks, cell cycle arrest 
and apoptosis. We also showed that siRNNs did not induce apoptosis in PBMCs 
compared to Plk1 small molecule inhibitor volasertib.
To conclude, small molecule inhibitors of Plk1 affect high number of proteins 
apart from Plk1 itself that might explain the side effects of the treatment. Specific 
RNAi -based drugs may help to overcome this issue in T-cell and B-cell ALL.
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11 INTRODUCTION
1.1 History of pediatric leukemia
For centuries doctors, philosophers and scientists were describing cases where 
people with the initial symptoms of tiredness, depressive mood, enlarged spleen 
and liver, progressive weakness, and bleedings were dying after several months, 
rarely years, from the onset of their symptoms. Despite that any person could 
become sick, children were considered disseminators of infections, so they usually 
were not admitted to the hospitals to the same extent as adults.1
The development of microscopy and medical science in the 18th and the 19th cen-
turies led to publications of cases that could be potentially identified as leukemia. 
Finally, in 1858 Rudolph Virchow and John Hughes Bennet came to conclusions 
for which they became accredited for defining “leukemia” as a separate clini-
cal entity. They succeeded to correlate and connect the clinical symptoms to the 
microscopical findings in the blood of the patients. The scientific discoveries of 
the 19th century, important for understanding of leukemia, continued. 
Ernst Neumann, a professor of Pathological Anatomy at Königsberg in 1860-80s, 
showed that erythropoiesis and lymphopoiesis take place in bone marrow (BM). 1 In 
1877, while still being a medical student, Paul Erlich established the use of triacid 
stain on a thin dried film formed from a blood drop. By such staining Erlich was 
able to distinguish between different types of cells and cellular components in the 
blood, and later he introduced a new classification of leukemia, dividing it into 
lymphoid (non-granular cells) and myeloid (granular cells) groups. Moreover, Erlich 
was the first to describe and implement a concept of a stem cell as a  hematopoietic 
ancestor for other blood cells. In 1900 Naegeli, a Swiss hematologist, defined a 
lymphoblast as a precursor to lymphocytes. Altogether, these findings made the 
basis for the classical diagnostic criteria of acute leukemia: circulating lympho- 
or myeloblasts.
Further, the development of epidemiology has facilitated the possibility to improve 
the knowledge about incidence of leukemia, particularly in children. In 1904, 
Frank Churchill, a physician from Chicago collected history about 15 cases that 
were regarded as “acute lymphatic leukemia” 2 with a detailed physical examina-
tion of the patients, their blood analysis and autopsy results. He showed that the 
disease affected newborns and older children, pointed out that symptoms mani-
fested  during the period of several days to several months, and also described the 
treatment options available at that time. Finally, Gordon Ward collected records 
of 1457 cases of different leukemia patients and in 1917 concluded that the acute 
form affects mostly children with a peak incidence between 0 and 5 years of age. 1,3
2As it became known that leukemia originates in the BM, doctors worked on a 
development of the instruments and techniques to perform sternal or tibial BM 
aspiration. 4 For example, in 1929 Arinkin, a Russian doctor, reported about 103 
successful sternal punctures, and this procedure was accepted to diagnose hema-
tological malignancies. 4,5 Nowadays, investigation of the BM biopsy with further 
immunophenotyping, molecular and cytogenetic profiling is crucial for clinical 
diagnostics of leukemia in order to choose the suitable treatment strategy. 6
1.2 Acute lymphoblastic leukemia 
In 2016, The World Health Organization introduced an updated classification of 
tumors of hematopoietic and lymphoid tissues, 7 where acute lymphoblastic leu-
kemia (ALL) is divided into two main groups: B-cell and T-cell (Figure 1). The 
symptoms of the disease include fatigue and exhaustion, nosebleeds, weight loss, 
skin pallor, petechiae and infections. 
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Figure 1. WHO classification of acute lymphoblastic leukemia, edition 2016 7
3According to the Swedish Childhood Cancer Foundation (Barncancerfonden), 
the combined share of leukemias and lymphomas accounts for about 42% of all 
cases of childhood cancers in Sweden. 8 Swedish National Board of Health and 
Welfare (Socialstyrelsen) provides a detailed statistical data on the incidence of 
ALL (Figure 2A and 2B). 6,9 The disease occurs mainly among children 0-4 years 
of age, affecting boys over girls, and shows a remarkable incidence stability over 
the years. 10 
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Figure 2. Incidence rate ALL among Swedish children 0-19 years old according to Social-
styrelsen statistical database.9,11 (A). Incidence rate of ALL (ICD-7) in Sweden in 2018 in 
different age groups (B).
41.2.1 Mutational profile
Acute leukemia is a hematological malignancy that arises from a so-called 
 leukemia-initiating cell. 12 This cell accumulates prenatal and postnatal muta-
tions, and undergoes clonal expansion, resulting in leukemia. The clinical picture 
develops when a high number of mutated lymphoblasts suppresses the cell growth 
of other hematopoietic cell lineages. Possibly, after treatment the primary clone 
undergoes clonal evolution and may become the cause of a relapse. In pediatric 
T-cell and B-cell ALL lymphoblasts express different surface antigens, called 
cluster differentiation (CD) and are identified as immunophenotypic markers of 
the cell maturation. 13,14 In the clinics, these markers are important for the future 
diagnostics and treatment. 
T-cell and B-cell ALL mutational profile includes more than 100 genes with studied 
aberrations, and some of them function as targets for treatment and/or prognostic 
markers. 15–18 The most common alterations in T-cell ALL are NOTCH1 mutations, 
cyclin-dependent kinase inhibitors 2A and 2B (CDKN2A/2B), TAL1 and Mixed 
Lineage Leukemia (MLL) gene rearrangements 15 (Figures 1 and 3). For B-cell 
ALL, EVT6-RUNX1 (known also as TEL/AML1), BCR-ABL1 (Breakpoint cluster 
region-Abelson murine leukemia viral oncogene homolog 1) and BCR-ABL1-like 
mutations, together with MLL rearrangement are the most common genetic aber-
rations. 19 BCR-ABL1 is a fusion gene, or Philadelphia chromosome (Ph+), that 
occurs in approximately 10% of B-cell ALL and hypodiploidy are associated with 
unfavorable prognosis. 17 In contrast, hyperdiplody, an increase in the number of 
chromosomes, occurs approximately in 30% of B-cell ALL and is an indicator of 
favorable prognosis in the patients. 
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Figure 3. The most common cytogenetic aberrations observed in children with B-cell ALL 
and T-cell ALL, Goroshchuk et al., Oncogene, 2019 15
5U.S Food & Drug Administration (FDA) and European Medicines Agency (EMA) 
are responsible for the approval of the newly developed drugs in the USA and 
European Union member states. On the FDA website there is a list of relevant 
pediatric molecular targets for different types of tumors, including T-cell and 
B-cell ALL. 20 Overall, the potential treatment targets are the groups of tyrosine 
or serine/threonine protein kinases, cell surface receptors, transcription factors, 
enzymes, or cytokines, that have been identified as influencers on cancer develop-
ment and prognosis. 
1.2.2 A historical perspective of treatment 
Despite the progress in diagnostics in the 19th century, there had been no effective 
treatment for acute leukemia for many decades. Nonetheless, accumulation of 
clinical reports on leukemia cases allowed to proceed with better understanding 
of the disease mechanisms that would lead to the development of a possible treat-
ment. Important steps were made after the discovery of the blood groups made 
by Karl Landsteiner in 1901.1 In 1947 Bessis and Bernard performed complete 
blood transfusion and achieved a short-term remission in a patient with leukemia. 
Blood transfusions were also widely used in children to compensate for severe 
hemorrhages. Also, physicians used potassium arsenite, mustard gas, busulphan 
and folic acid antagonists to treat leukemia. It was shown that these substances 
have a toxic effect on the hematopoietic system and can therefore eradicate the 
leukemic blasts. 
By 1960s, there were several chemotherapeutical agents used to treat leukemia 
patients that were approved by FDA, such as adrenal corticosteroids and adreno-
corticotrophic hormone; purine analog 6-mercaptopurine (6-MP); folic acid 
antagonist methotrexate (MXT); vincristine and cyclophosphamide. However, 
most of the drugs showed only temporary efficiency and many patients relapsed 
after treatment. The revolution happened when Donald Pinkel, an American doctor 
from St. Jude Hospital became inspired by multi-drug combinations in treatment 
of tuberculosis and Hodgkin disease. 21 He wrote a new protocol of intensive treat-
ment with “armamentarium” of existing antileukemic drugs “The Total Therapy 
V Study”, that also included irradiation of the spine and cranium. In 1968 Pinkel 
and colleagues published a revolutionary paper reporting the long-term remis-
sion and high survival rate in children with leukemia. 22 This paper completely 
changed the approach in the treatment of childhood leukemia. It provided a basis 
for  further improvements and protocol optimizations by different collaborative 
projects: Acute Leukemia Group B, Nordic Pediatric Hematology Oncology 
Group, Dutch Childhood Oncology Group, Berlin Frankfurt Munster Group and 
others. 21,23 Further studies resulted in stratifying patients into different risk groups, 
and understanding the role of genetic and chromosomal alterations in the disease 
prognosis. 23 
6After years of work in hematology-oncology, Donald Pinkel identified four main 
obstacles in treating acute leukemia, such as (1) primary and secondary drug 
resistance; (2) isolated relapse in central nervous system; (3) high and overlying 
toxicities of existing drugs; (4) desperation to find the treatment. 21 More than 50 
years later, his statements are still valid, except the one – desperation to find the 
treatment. There are many questions on how to help the patients waiting to be 
answered, and this thesis is one of the attempts to find a novel treatment for acute 
pediatric leukemia and improve long-term outcomes in patients. 
1.2.3 Risk stratification 
The development of the first chemotherapeutic protocol in the USA was followed by 
the rise of multiple national programs to treat pediatric ALL. In Sweden, Denmark, 
Finland, Norway, and Iceland, hematologists and oncologists apply protocols from 
the Nordic Society of Pediatric Haematology and Oncology (NOPHO). With one 
of them, NOPHO ALL-2000, it was possible to achieve a relatively long period of 
complete remission (CR), 50% 5-year overall survival (OS) and event-free survival 
(EFS). 24 In 2008 NOPHO set an aim to improve therapeutic strategy in patients 
with T-cell ALL and Philadelphia negative (Ph-) B-cell ALL. Ten years, later in 
2018 there were published the results on response to treatment and survival rates. 25 
According to NOPHO ALL-2008 protocol, at first patients underwent stratifications 
at three time points: at diagnosis, 1 month and 3 months after diagnosis. Children 
were stratified into three risk groups: standard, intermediate, and high-risk. At the 
final stratification at 3 months after the diagnosis, approximately 50% of patients 
were included in a standard risk group as they satisfied the following criteria:
• B – cell lineage;
• white blood cells count (WBC) < 100 cells;
• minimal residual disease (MRD) < 10-3 day 29;
• no intermediate or high risk criteria/cytogenetics;
• no central nervous system 3 involvement at diagnosis.
Intermediate and high-risk groups included approximately 45% of patients. 
Stratification criteria included a particular cytogenetic profile, i.e. hypodiploidy or 
MLL-rearrangement, presence of blasts in cerebrospinal fluid, and MRD levels. 26 
1.2.4 Treatment strategy. Personalized therapy
The protocol NOPHO ALL-2008 includes different combinations of drugs based 
on the risk profile of each patient. The ALL treatment is divided into three phases: 
induction, consolidation and maintenance. 25,26 The induction phase of standard 
7risk patients includes treatment with one of the glucocorticoids (dexamethasone 
or prednisolone), vincristine, MTX, cytarabine, doxorubicin, pegylated (PEG)-
asparaginase and 6-MP. In case of central nervous system involvement, intrathecal 
treatment is prescribed. The consolidation protocol includes all abovementioned 
drugs except doxorubicin and dexamethasone. Maintenance therapy phase of 
standard risk group includes the drugs from induction phase (excluding doxo-
rubicin) with additional considerations of folinic acid and carboxypeptidase. 25 
The expected duration of the treatment according to the protocol is 2.5 years, 
however, it always depends on the patient response. 26
The chemotherapeutical protocol aims to attack the cancer cell by targeting dif-
ferent cellular processes. Dexamethasone and prednisolone suppress cytokine 
production and induce a specific glucocorticosteroid-mediated cell cycle arrest and 
apoptosis. 26,27 Vincristine belongs to a group of vinca alkaloids that destabilize the 
microtubule system of cancer cells and act as antimitotic drugs. Doxorubicin and 
daunorubicin belong to a group of anti-tumor antibiotics – anthracyclines. They 
induce DNA-damage via intercalation the DNA or inhibition of the enzyme topoi-
somerase II, also causing oxidative stress, irreversible disruption of mitochondrial 
functions and deregulation of iron homeostasis. 28,29
The chemical structure of cytarabine is similar to nucleotide cytosine, therefore 
the drug incorporates into the DNA as a false base, leading to DNA synthesis 
inhibition in cancer cells. MTX is another drug that disrupts purine synthesis, 
it belongs to a group of antifolates. 30 Folic acid is an important part of the cell 
metabolism. MTX chemical structure is similar to the one of folic acid, and the 
drug competitively inhibits the enzyme involved in folic acid metabolism. This 
inhibition leads to a reduction in DNA synthesis and disturbed DNA methylation, 
followed by apoptosis. 
Asparaginase catalyzes metabolism of a nonessential amino acid L-asparagine. 31,32 
In case of leukemia, L-asparagine cannot be synthesized by cancer cells, therefore, 
they are dependent on the external sources of asparagine. Fast reduction of aspara-
gine levels in blood, before the amino acid enters the cells, results in disrupted 
asparagine-dependent protein synthesis and a consequent cell death. 
The last decades were enlightened by new successful drug developments. 33–35 FDA 
approved tyrosine kinase inhibitors (TKIs) imatinib and other BCR-ABL1 inhibitors 
in patients with Philadelphia chromosome-positive (Ph+) ALL. TKIs are designed 
to bind to a specific region in ATP-domain, block the function of the mutated protein 
kinase and inhibit cancer cell proliferation. 36 These drugs significantly improved 
survival of the patients. 37,38 Immunotherapy is another exciting field that acts on 
activating the immune cells that were previously “tricked” and “blinded” by cancer 
8cells and cancer microenvironment. Natural killer (NK) cells targeted therapies, 
anti – cancer vaccines monoclonal antibodies and chimeric antigen receptor (CAR) 
T-cells are in the line of clinical trials and approved treatments. 33,39–41
Overall, the approved intensive antileukemic treatment is efficient in eradicating 
of the lymphoblasts. However, short and long-term adverse reactions are important 
drawbacks of existing anticancer treatments.
1.2.5 Adverse effects of the current therapies 
Even though the treatment is efficient towards cancer, 24 it causes multiple unwanted 
side effects by affecting normal cells. For example, folate receptors are expressed 
on both cancerous and non-cancerous cells, limiting the use of MTX. The severity 
of toxicity might be of a low grade and transient; however, sometimes the adverse 
reactions can lead to a lethal outcome. For example, chemotherapy and targeted 
drugs have a potential to induce tumor lysis syndrome that develops in case of 
intense cell proliferation and high tumor burden which is common in patients with 
hematological malignancies. 42,43 This serious condition can manifest first by changes 
in blood or changes in biochemical parameters, and later – with clinical symptoms 
that require an immediate and intensive treatment. The symptoms include high 
fever, renal and cardiac failure, and vary in severity, often leading to mortality.
Among the common side effects of corticosteroids are changes in the body weight, 
hypertension, immunosuppression with consequent increase of infection risk. 44 
Due to the decreased cytokine production, patients have less pronounced clinical 
picture of life-threatening inflammatory processes. Additionally, treatment with 
steroids can induce withdrawal syndrome with plethora of symptoms from high 
fever and weakness to anorexia and mood changes.
As mild reactions, vincristine can provoke loss of reflexes, bone pain and/or 
constipation. 26 However, it can also lead to severe neuropathy. Topoisomerase II 
inhibitors, such as doxorubicin or etoposide induce multiple side effects such as 
BM suppression, hair loss, gastro-intestinal tract damage, reduced muscle strength 
and cardiotoxicity, including cardiomyopathy and irreparable heart failure. 45 
Moreover, treatment with anthracyclines is associated with an increased risk of 
the secondary myeloid leukemia. 6 PEG-asparaginase can induce a specific allergic 
reaction with local redness and rashes, pancreatitis, thromboembolic complica-
tions, hyperglycemia or hyperbilirubinemia. 32 In severe cases PEG-asparaginase 
induces anaphylaxis. Cytarabine, one of the most used drugs in pediatric ALL, 
provokes multiple side effects, which are often dose-limiting factors. Among them 
are leukopenia, thrombocytopenia, rashes, fever, gastrointestinal inflammation, 
personality changes and neuropathy. 26 
9Immunotherapy, including anti-CD19/CD22 CAR T-cells treatment became one 
of the highlights in cancer therapy in recent years. 33,46 However, this type of treat-
ment is associated with a severe condition called cytokine-release syndrome. 47 
An uncontrolled release of interferon gamma (IFNγ) and interleukins (IL), IL-6 in 
particular, results in systemic response including high fever, neurologic, respira-
tory, gastrointestinal and hepatic symptoms, and requires intensive monitoring 
and care. 48,49 
Small molecules also face the problem of unpredicted toxicities. 50,51 One study 
showed that the crystal structure and presence of pseudosequences of a serine/
threonine protein kinases increased their promiscuity to a specific compound/small 
molecule, that might result in unspecific effects. 52 For the group of TKIs some 
of the common adverse reactions were reported, such as myelosuppression, skin 
rash, fatigue, diarrhea, and hypertension. 53 It is also known that point mutations 
in the drug targets later lead to the drug resistance. 54 Notably, the small molecule 
inhibitors may affect other proteins and pathways due to structural similarities 
between the proteins. At the same time, there is a possibility of disruption of 
the protein or receptor function due to unspecific downstream effect, without 
applying a targeted inhibitor. 55 For example, in vivo studies suggested histone 
deacetylase inhibitors (HDACi) with a monoclonal antibody to be a promising 
combination for myelodysplastic syndrome (NCT02936752). 56 HDACi inhibit 
expression of PD-L1 surface proteins, important for the tumor surveillance, and 
therefore, enhance the effect of monoclonal antibodies. However, the same effect 
of HDAC surface proteins degradation is observed by combining the antifolate 
pemetrexed and phosphodiesterase inhibitor sildenafil, despite that they do not 
aim to inhibit HDAC. 
To conclude, there is a need for more knowledge in the “on-target” and “off-target” 
interactions, that might be used in the future to optimize treatment protocols and 
reduce adverse effects in patients. 
1.3 Polo-like kinase family
In 1970s-1980s the scientists Nurse, Hartwell and Hunt described the cell cycle 
initiation and progression via genes responsible for checkpoints between the 
phases and characterized the key regulators of the cell division – cyclins and 
cyclin-dependent kinases (CDKs). In 2001 they were awarded the Nobel Prize 
for their discoveries. 57 Later it was shown that there are many more proteins that 
orchestrate the process of cell division. 58–60 The cell cycle of eukaryotic, includ-
ing human cells, consists of interphase and mitosis. Interphase includes G1, S and 
G2 phases, and is required for the DNA replication and preparation for mitotic 
division. 58 Mitosis is divided into four phases (prophase, metaphase, anaphase, 
10
telophase) and results in the formation of two cells via cytokinesis. The transi-
tion between the different phases is supported by checkpoints that ensure correct 
execution of all steps in the cell cycle. 
The Nobel Prize press-release in 2001 stated that the knowledge about the regu-
lators of the cell cycle can be applied for cancer diagnostics, and in a long-term 
perspective – for cancer treatment. 57 In 2019 more than 7 000 trials targeting cell 
cycle proteins in various diseases, from degenerative disorders to cancer, were 
registered by the U.S. National Library of Medicine. 61 The available drugs target 
not only cyclin-dependent kinases (CDKs) and cyclins, but also a number of other 
cell division regulators, including polo-like kinases (Figure 4). 
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Figure 4. Schematic description of the functions of different polo-like kinases in the cell 
cycle. The wider the line, the higher is the protein level of a particular kinase. Reprinted 
from Goroshchuk et al., Oncogene, 2019 15
In 1980s, experiments in Drosophila melanogaster showed that mutations in the 
polo gene disrupted the function and structure of centrosomes and induced abnor-
malities in mitotic spindles formation during the mitotic process. 62 In humans the 
discovered protein was called polo-like kinase due to a structural similarity with 
the protein encoded by polo gene. 63 Later it has been shown that the structure of 
11
different Plk family members (Figure 5) is conserved throughout many species. 
The N-terminal in all Plks has an ATP-binding kinase domain that is one of the 
main targets for drugs, while the C-terminal contains a polo-box domain (PBD) 
which is a unique feature of the Plk family. 64,65 The Plk family proteins were 
identified both in cytoplasm and nucleus during the different cell cycle phases. 
Translocation to the nucleus is regulated by nuclear localization signal (NLS) that 
has already been identified on Plk1 (black mark in Figure 5) 66, however, more 
studies are needed to confirm the NLS sequences in Plk family members (yellow 
marks in Figure 5). 67 
D-box PB2PB1NLS
603 aa
T-loopATP
Plk1
685 aa
T-loopATP
Plk2
646 aa
T-loopATP
Plk3
970 aaPlk4
PB3PB2PB1ATP T-loop
336 aaPlk5
ATP
Kinase domain
Polo box domain
Cryptic Polo box domain
PEST (proline-glutamic-acid--
serine-threonine motif )
Proven nuclear localization signal
Suggested location for
 nuclear localization signal
Figure 5. The structure of all five Plk family members includes conserved serine/threo-
nine kinase (N-terminal) domain and a conserved domain with two or more polo boxes 
(C-terminal domain). Modified from Goroshchuk et al., Oncogene, 2019 15
1.3.1 Polo-like kinase 1
Plk1 is the most studied kinase among all the family members. The transcription 
of Plk1 is regulated according to the process of cell division. There are two key 
factors, that coordinate the cell cycle: retinoblastoma (Rb) gene and E2F. While 
Rb suppresses the Plk1 promotor 68,69, members of the E2F family, E2F1-E2F3 
activate transcription of Plk1. 70 The levels of Plk1 messenger RNA (mRNA) are 
cell-type dependent and change during the cell cycle progression. The highest 
expression of Plk1 is detected in BM, placenta, liver, pancreas, thymus, and testis, 
supporting the idea that Plk1 is important for mitotically-active cells (Figure 6). 71,72 
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Figure 6. Plk1 expression data from 477 samples uploaded to the publicly available 
databases, indicating that Plk1 is highly expressed in actively dividing cells, i.e. in bone 
marrow (BM) or malignant lymphoblasts in peripheral blood (PB) 
Before the G2 phase, Plk1 is detected in cytoplasm when the kinase domain 
is autoinhibited by the PBD, while the active phosphorylated form of Plk1 is 
located in the nucleus. 73–75 There are two main active sites on the N-terminal of 
Plk1 protein, Ser137 and Thr210; in autoinhibited state Ser137 forms a hydrogen 
bond with Glu126 from the PBD. Ser137 and Thr210 phosphorylation relieves 
this bond and activates the kinase. 75,76 Plk1 appears at multiple events during the 
cell cycle (Figure 4). Despite that initially the role of Plk1 was shown in G2 and 
mitosis progression, more experimental evidence points out that Plk1 is important 
in G1 and S phases. For example, proper Plk1 degradation via ubiquitination is 
important for G1/S progression. 77 Plk1 becomes active after phosphorylation on 
Thr210 by Aurora kinase A and its cofactor Aurora Borealis (Bora). The phospho-
rylated Plk is then recruited to the nucleus during the G2 phase. 76,78 There Plk1 
regulates centrosome maturation and correct microtubule – kinetochore attach-
ment. 79,80 Plk1 ensures correct G2/M transition due to the interplay between Plk1 
and complex Cdk1-cyclin B1. 59 Before the M-phase, Cdk1-cyclin B1 is inhibited 
by kinases Wee1 and Myelin-transcription factor 1 (Myt1). Plk1 inhibits Myt1 
and promotes Wee1 degradation 81, together with phosphorylation and activa-
tion of Cdc25C phosphatase that dephosphorylates Cdk1 and promotes enter to 
mitosis. 82 The process of cleavage furrow formation during cytokinesis is also 
regulated by Plk1. In this case, Plk1 phosphorylates proteins Protein regulator of 
cytokinesis 1 (PRC1), Kinesin family member 23 (KIF23) and RACGAP1 (Rac 
GTPase activating protein 1) that activate enzyme Ras homolog family A (RhoA) 
and ensure separation of the two cells. 59,83 When Plk1 has completed its functions, 
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it is ubiquitylated and degraded by Anaphase-promoting complex/cyclosomeCadherin 1 
(APC/CCdh1) at the end of mitosis. 65,84,85 Nondegraded Plk1 causes a reduction in 
APC/CCdh1 activity, a defect in the destruction of mitotic cyclins, and a delay in 
mitotic exit. Furthermore, recent studies also revealed functions of Plk1 that are 
not connected to the cell cycle: Plk1 regulates vascular homeostasis and supports 
response to angiotensin II in cardiomyocytes. 86
Not only normal cell cycle, but the stress response mechanisms and malignant 
transformation are dependent on Plk1 as well. In 1996 Lane and Nigg injected 
highly specific anti-Plk1 antibodies in HeLa cells in order to investigate the func-
tional role of Plk1 inhibition in cancer cells. 87 The injection resulted in abnormal 
distribution of chromatin, unseparated centrosomes, and overall failure in the cell 
division. It has been also shown that Plk1 is involved in centriole reduplication 
and maturation process during the S-phase in malignant cells. 88 In case of DNA 
damage, Plk1 is one of key targets of DNA damage response signaling cascade. 
The interplay between synthesis and degradation of APC/C and Cdk1-cyclin B1 
complexes supports the one-way progression of the normal cell cycle. In case of 
early DNA damage, Plk1 phosphorylation is prevented by Aurora A inhibition; while 
later induction of DNA damage signaling in G2 phase leads to Plk1 degradation by 
APC/CCdh1. However, in turn, Plk1 can inhibit DNA damage mechanisms response 
and promotes the checkpoint recovery via inhibition of Wee1, ataxia-telangiectasia 
and Rad3-related protein (ATR)-Checkpoint (Chk) 1, ataxia-telangiectasia mutated 
(ATM)-Chk2, and p53 axes. Several studies showed the role of Plk1 in a complex 
interplay with p53 in normal and cancer cells. 89–91 Plk1 either phosphorylates 
E3 ubiquitin-protein ligase TOPORS and G2 and S phase-expressed protein 1 
(GTSE1) that activate p53 suppressor E3 ligase MDM2, or directly phosphoryl-
ates p53, leading to its inhibition. In turn, p53 binds to Plk1 promoter region and 
directly inhibits Plk1 expression, regulating mitotic progression. 89 Overall, it has 
been shown that without Plk1 cancer cells are unable to continue cell division 
and Plk1 inhibition induces mitotic catastrophe after checkpoint disruptions or 
DNA damage. 81,92 
Since Plk1 is involved in mitosis, the protein has been extensively studied in rela-
tion to cancer. RNA sequencing data combined with survival analysis showed that 
Plk1 upregulation has tumor-dependent positive, negative or neutral influence on 
prognosis in cancer patients. 93 For example, there are multiple studies that reveal 
an oncogenic role of Plk1 that might contribute to a poor prognosis in case of lung 
adenocarcinoma, gastric, bladder or kidney clear cell carcinoma patients. 71,72,93–99 
At the same time, no effect on survival was observed in patients with ovarian 
cancer or cervical squamous cell carcinoma. According to the data analysis of 
the TARGET ALL and TCGA Acute Myeloid Leukemia (AML) studies in XENA 
browser, there is no significant connection between the level of Plk1 expression 
and survival of the patients. 100
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1.3.2 Polo-like kinase 2
Unlike Plk1 that is expressed in dividing cells, Plk2 is ubiquitously expressed 
throughout human tissues. 59 Plk2-/- fibroblasts and embryos are viable, although 
they demonstrate an increased duplication time and slow growth. Both mRNA and 
protein levels of Plk2 peak during the G1 and early S-phases. In normal cells, Plk2 
is involved in centriole duplication during G1/S transition.59,101 
The potential role of Plk2 in cancer has also been studied. Plk2 CpG islands are 
epigenetically silenced in a number of hematologic malignancies (e.g., Burkitt 
lymphoma, AML, myelodysplastic syndrome (MDS), multiple myeloma) sug-
gesting the tumor suppressing role of Plk2. 102 It was also shown that higher 
Plk2 CpG methylation levels correlated with a more resistant cancer cell pheno-
type elucidating potential involvement of Plk2 in drug sensitivity and therapy 
response. 102,103 However, some studies showed that Plk2 phosphorylates mutated 
p53. In this case Plk2 knockdown might be used to combat chemo-resistance in 
p53-mutated tumors. 104
1.3.3 Polo-like kinase 3
The biological role of Plk3 in different types of cells is disputable. 59 In general, it has 
been shown that Plk3 is involved in the cell cycle by regulating G1/S transition. 67 
At the same time, it has been shown that Plk3 phosphorylates the anti-apoptotic 
protein Bcl-xL at G2/M checkpoint and promotes G2 arrest. 105 During the DNA 
damage and stress response Plk3 is able to phosphorylate p53. 106 In malignancies, 
apart from expression data showing Plk3 loss in several cancer types, 107 it was 
demonstrated that Plk3-/- mice exhibited enhanced angiogenesis and were prone 
to tumor development at older age. 108 Recently it has been found that Plk3 inhib-
its the activity of an oncogene hypoxia-induced gene (HIF1a) known to promote 
angiogenesis and glucose metabolism in cancer. 109,110 Therefore Plk3 has been 
proposed to play a tumor suppressor role 107,111 
1.3.4 Polo-like kinase 4
Plk4 protein structure is similar to other Plk family members, however, the 
C-terminal part contains a unique structure called the cryptic PBD (Figure 5). 84,112 
Due to this difference, the regulation of Plk4 activity is distinct from that of Plk1-3 
which utilize PBD dimerization for autoregulatory functions. Plk4 mRNA and 
protein expression is low during G1- and S-phase and increases during mitosis. 
It has been shown that Plk4 deficient fibroblasts cannot progress and die early 
in the development. 59 113 The death at one week of embryonal development fol-
lowed a complete Plk4 gene knockout, while heterozygous mice develop  cancer 
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in the older age, having an increased level of cyclin B1 and multiple spindles 
in the cancer cells. Plk4 is almost exclusively localized on centrosomes, and is 
involved in centriole and basal bodies duplication during the S-phase. 114–116 As 
observed in overexpression experiments, increased levels of Plk4 lead to tri- and 
tetrapolar spindles formation. 115
The role of Plk4 in cancer is also being extensively studied since Plk4 is fre-
quently overexpressed in cancer cells. Some studies showed that Plk4 inhibition 
leads to anti-cancer therapy sensitization by limiting the replicating ability of 
cancer cells. 117 It was also found that Plk4 has centrosome-independent functions 
that promote cancer cell migration and invasion. 118 As an increased expression of 
Plk4 promotes chromosomal instability, the protein was qualified as a  desirable 
target for anti-cancer drug development. 119,120 Currently, phase I clinical trial is 
recruiting patients with a relapsed or refractory AML for treatment with Plk4 
inhibitor CFI-4000945 fumarate (NCT03187288). 120 
1.3.5 Polo-like kinase 5
The recently discovered Plk5 is located in nucleolus and is present in neuronal 
and reproductive tissues in vertebrates. 121,122 Human Plk5 has a stop codon at 
exon 6 that leads to synthesis of truncated human Plk5 protein. 59 The mechanism 
of action of Plk5 is different from other Plk family members, for example, the 
stress-response mechanism in Plk5 is independent of p53. 121 In neurons and glia, 
Plk5 is required for neurites growth. 122 In humans, an increased Plk5 promoter 
methylation is observed in aggressive astrocytomas, suggesting Plk5 as a treat-
ment target in brain tumors. 121,123 
1.4 Plk1 inhibition
Since Plk1 is highly expressed in different cancer types, Plk1 has become an 
attractive target for anti-tumor drug development. To date, several approaches have 
been tested. For example, small molecule inhibitors bind to different domains in 
already synthesized Plk1 protein, while antisense oligonucleotides (ASOs) and 
short interfering RNA (siRNA)-based drugs aim to induce Plk1 mRNA cleavage. 
Each of these treatments will be discussed below. 
ASOs are single-stranded “gapmers” with “gaps” of several DNA nucleotides 
inserted between chemically modified RNA nucleotides. 124 ASOs enter the cell 
without being conjugated to a specific delivery domain in order to cross the cell 
membrane bilayer. 125 The enzyme RNaseH identifies and recruits to DNA:RNA 
duplexes, inducing the cleavage of the target mRNA. 126 Several attempts to apply 
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such strategy to inhibit Plk1 showed that antisense inhibition of Plk1 mRNA using 
phosphorothioate-modified ASOs led to loss of cell viability and proliferation 
arrest. 127,128 The injection of ASOs lead to anti-tumor activity on the lung cancer 
cells in xenografted nude mice. However, the most promising treatment results 
with ASOs were reached in targeting liver and central nervous system. 129 As for the 
beginning of 2020, no clinical study was initiated to use ASOs in ALL treatment. 
In contrast to ASOs, small molecule protein inhibitors have been more successful 
in reaching the cancer patients in clinical trials.
1.4.1 Plk1 inhibition by small molecules 
Among the important advantages of small molecules are high penetration through 
the cell membrane and a relatively inexpensive production. Plk1 has two “drug-
gable” domains – the kinase domain with an ATP-pocket and the PDB, therefore 
many ATP-competitive or PBD inhibitors have been developed. However, PBD 
inhibitors developed up to date, such as poloxin or thymoquinone turned out to 
be non-specific alkylators. 130 At the same time, new papers have been published 
on synthetic PBD inhibitors, indicating an ongoing interest in this way of Plk1 
inhibition. 131,132 However, there are no ongoing clinical trials on PBD inhibitors. 
In contrast, ATP-competitive Plk1 inhibitors that induce G2 arrest and trigger 
apoptosis in cancer cells have been analyzed in multiple past and ongoing clini-
cal trials. 15,72,133–135 
One of the earliest ATP-competitive inhibitors is BI2536. It belongs to a group 
of dihydropteridinones and induces prometaphase arrest with the formation of 
monopolar spindles, mitotic disruption and a cell apoptosis in multiple cancer cell 
lines. 136–138 The IC50 value of BI2536 is 0.83 nM, 3.5 nM, and 9.0 nM towards 
Plk1, Plk2, and Plk3, respectively. 139 In successful trials 23% of the patients had a 
complete remission (CR) for longer than 3 months. The main dose-limiting toxici-
ties (DLTs) reported were reversible neutropenia with or without infection, nausea, 
fatigue and anorexia of mild to moderate intensity (Figure 7). 61 Despite the met 
endpoints and antitumor effect of BI2536 in patients with metastatic tumors or 
myeloid leukemia, BI2536 did not go beyond phase II/IIa of clinical trials. 
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Figure 7. The most common side effects, reported from clinical trials with Plk1 small 
 molecule inhibitors BI2536, volasertib and NMS-1286937 as single drugs. Enrolled patients 
had solid tumors and hematological cancers. One study (NCT01971476) was conducted in 
children. ALT, alanine aminotransferase; AST, aspartate aminotransferase; ECG, electro-
cardiogram; QT, interval that describes contraction and relaxation of cardiac ventricles
After BI2536 followed another dihydropteridinone derivative and ATP-competitor 
named volasertib (BI6727). Volasertib was shown to be an efficient Plk1 inhibi-
tor, with an IC50 value of 0.87 nM. However, due to the structural similarity of 
the ATP-pocket, volasertib also inhibits Plk2 and Plk3 (IC50 values of 5 nM and 
56 nM respectively). 140 Volasertib has been tested in multiple pre-clinical trials, 
both as a single agent and in a combination therapy and showed a potential for the 
treatment of resistant forms of leukemia. 138,141–144 Volasertib has also been exam-
ined in several phase I-II clinical trials and initially showed acceptable tolerability 
and safety for patients, with no increase in death rate. 145,146 Most commonly, the 
effects of volasertib in patients were studied in combination with other drugs, such 
as cytarabine, azacytidine or the histone deacetylase inhibitor belinostat. 147–151 
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However, some studies were withdrawn or terminated before achieving the main 
objectives, or co-administration of volasertib with abovementioned drugs did not 
improve survival of the patients. 152 In phase III trials POLO-AML-2 combination 
with cytarabine showed a higher incidence of neutropenic fever and fatal infec-
tions (Figure 7). 153
The third Plk1 small molecule inhibitor, NMS-1289637 (NMS-P937, onvansertib) 
has been developed recently. 154–156 NMS-1289637 specifically and reversibly 
inhibits Plk1 at an IC50 value of 2 nM, showing activity in multiple cell lines, with 
a minimal effect on Plk2 and Plk3. 155 After promising in vivo experiments, the 
possibility of an oral formulation, beneficial pharmacokinetics and pharmaco-
dynamics, and a proven antitumor effect led to the start of a phase I trial in adult 
patients with metastatic and advanced solid tumors. 157 As major dose-limiting 
toxicities (DLTs) reversible anemia, thrombocytopenia, leukopenia and neutro-
penia were reported (Figure 7). Therefore, the drug was recommended for the 
future investigation and was recently enrolled in a phase II clinical trial on solid 
tumors and acute leukemia. 158 
In summary, the area of small molecule inhibitors is expanding as more pharma-
ceutical companies aim to use the ATP-pocket to block mitotic activity of Plk1.
1.4.2 RNA interference against Plk1
1.4.2.1 RNAi: from flowers to humans
The discovery of RNA interference (RNAi) began in 1990 with an experiment on 
the petunia flower, where the effect of RNAi was observed for the first time. 159 
However, there was no clear explanation of the phenomenon. Later, in 1998 Craig 
Mello and Andrew Fire described and explained the process of RNAi in the nema-
tode Caernorhabditis elegans (C.elegans). 160 They were awarded a Nobel Prize in 
Physiology and Medicine in 2006 for their studies. 
The process of RNAi is very elegant and is based on the evolutionary developed 
response towards viral intrusion and is used to disrupt the expression of alien genes 
in cytoplasm. When a double-stranded (ds)RNA molecule enters the eukaryotic 
cell, it is cleaved by a specific enzyme Dicer into siRNAs (up to 21 nucleotides). 
Further, the double-strand RNA – binding protein (dsRBP) binds to the siRNA/
Dicer complex and together with the enzyme Argonaute (Ago) 2 they form the 
RNA-induced silencing complex (RISC). In this complex, the passenger (sense) 
siRNA strand is removed, while the guide (antisense) strand is retained and is used 
as a template to identify the target mRNA that is cleaved by Ago2 in a sequence-
specific manner. Consequently, the absence of the mRNA prevents the synthesis 
of the corresponding protein. 
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1.4.2.2 RNAi: from bench to bed
In oncology, the opportunity to modify mRNA expression opened the way to 
target genes crucial for cancer cells, i.e. responsible for the cell proliferation or 
migration. 161 However, the potential of siRNA-based therapies is still limited by 
different issues such as delivery inside a target cell, immune response, escape to 
the cytoplasm, and overcoming these issues has been a major task. 125,126 As the area 
of RNAi-based therapies is quickly expanding, several rules have been set on how 
to design siRNAs for in vivo studies and future clinical implementation. 126,162,163 
First, the size and the negative charge of siRNA prevents the passive diffusion 
across the bilayer cell membrane. The siRNA molecule is too large and too nega-
tively charged for a passive diffusion, and in a modified state can be up to 70 times 
larger than a small molecule drug (Figure 8). 126
Volasertib
13 000 Da600 Da
Molecular weight
100 Da
10 000 Da
siRNA 
Figure 8. Schematic comparison of molecular weight of the Plk1 small molecule inhibi-
tor and siRNA.
Therefore, multiple structures that can carry siRNA as cargo inside the cell have been 
developed. These include antibodies, cell-penetrating peptides, lipid or polymer 
nanoparticles, that can deliver the siRNA molecule into the cytoplasm via surface 
receptor-mediated endocytosis. 126,161,164,165 The issue with lipid nanoparticles arises 
from the complexity of the structure due to the involvement of up to five compo-
nents. Each component has a different level of toxicity, that can induce unspecific 
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and adverse effects. Moreover, it is difficult to deliver the lipid nanoparticles to 
the cells other than hepatocytes. 125 In contrast, the clinically success ful choice 
of the target and delivery domain was made with acyloglycoprotein receptors on 
hepatocytes and liver-targeting ligand tris N-acetylgalactosamine (GalNAc), that 
will be discussed later. 
Second, upon the injection, the siRNA can be rapidly taken up and cleared from 
the blood by scavenger receptors on kidneys and the liver. Therefore, siRNA 
molecules have to be able to evade destruction by serum nucleases, have a long 
circulation time, escape renal clearance or opsonization. 165 
Third, throughout the human evolution, the cells have developed a tool to iden-
tify the alien RNAs called pattern recognition receptors, for example Toll-like 
receptors, dsRNA-dependent protein kinase (PKR) and retinoic acid inducible 
gene 1 protein (RIG1). 166 Toll-like receptor 3 (TLR3) is expressed on fibroblasts, 
epithelial and dendritic cells, and recognizes siRNA that interacts with the cell 
surface or inside the endosome. TLR7 and TLR8 are expressed on dendritic cells, 
B cells, monocytes and macrophages, and react on siRNA. Finally, PKR and RIG1 
proteins detect siRNA in the cytoplasm. As a response mechanism, the immune 
cells produce IFNα/ß/γ and IL1/IL6/IL12. Therefore, in order to be able to exe-
cute its function in vivo, therapeutic siRNA should be synthetically masked from 
the  pattern recognition receptors which are a part of the innate immunity. 163,164 
Moreover, the siRNA sequence, the chemical structure and used delivery vehicles 
can also induce the immune response. 166 
Last but not the least, there is an issue of facilitation and controlling of the siRNA 
escape from the endosome. There are different types of endocytosis, such as phago-
cytosis, clathrin-dependent endocytosis, caveolae formation, micropinocytosis, 
but all of them exhibit an issue for siRNA delivery inside the cytoplasm in a non-
toxic manner. 164 The exact mechanism underlying this process is still unknown. 
However it has been suggested that a pH drop inside the endosome could lead to 
endosomal membrane destabilization, and the experimental data confirm siRNA 
escape into the cytoplasm and induction of RNAi. 125,167,168
The discovery of acyloglycoprotein receptors eligible for siRNA uptake on the 
hepatocytes surface resulted in an FDA-approved RNAi-based drugs. Patisiran 
(“Onpattro”) was the first drug to be approved and is used to reduce transthyretin 
mRNA and treat transthyretin – mediated amyloidosis. Patisiran is encapsulated 
in lipid nanoparticles, coated with apolipoprotein E (ApoE), and after the intra-
venous injection it travels with the blood stream, gets to the liver and binds to 
the ApoE receptors on the liver surface. 49,169 The results of multiple clinical trials 
showed that patisiran induces mild infusion-related side effects such as back pain, 
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flushes, nausea, and/or abdominal pain. 170 Moreover, during the three – four years 
of clinical use only mild reactions were observed in some patients. Therefore, 
patisiran is considered to be a safe and efficient treatment. The second drug, 
givosiran, was evaluated in patients with an acute intermittent porphyria. 171,172 
The drug is used subcutaneously and executes liver-targeting ligand GalNAc as 
a delivery  vehicle for siRNA. GalNAc binds to acyloglycoprotein receptors and 
assists siRNA entry into a liver cell to reduce mRNA of delta aminolevulinic acid 
synthase 1 (ALAS1). Among the most common reported adverse events in clinical 
trials were nasopharyngitis, abdominal pain, nausea, diarrhea, back pain, fatigue, 
headache, injection-site reaction, oropharyngeal pain, rash, and vomiting. 171 In 
general, adverse reactions were reversible of mild-to-moderate severity, therefore 
givosiran was approved by FDA in 2019 and entered the pharmaceutical market 
under the trade name “Givlaari”. 172,173
Notably, there were also attempts to target Plk1 using stable nucleic acid – lipid 
nanoparticles (SNALP) encapsulation as a delivery system for RNAi-based inhibi-
tor TKM – 080301 (TKM-Plk1) in adult patients with hepatocellular carcinoma. 174 
The study showed a good tolerability of treatment, with fever, fatigue, peripheral 
edema, noncardiac chest pain, and malaise as reported adverse reactions. Three 
cases of patients’ death were considered as not related to TKM-Plk1 treatment. 
Despite this, due to a modest effect on tumor, TKM – Plk1 was not recommended 
as a single agent to treat hepatocellular carcinoma. As of the beginning of 2020, 
there have been no clinical studies initiated with siRNA Plk1 as a treatment for 
any kind of leukemia.
1.4.2.3 RNAi prodrugs
As it has been mentioned before, siRNA-based therapy has a great potential to 
treat cancer, and multiple research groups work to optimize the delivery approach 
for this type of drugs. One of the aims in this thesis was to evaluate the effect of 
modified siRNAs – RNAi-prodrugs, called short interfering ribonucleic neutrals 
(siRNNs) (Figure 9) in ALL. 167
siRNN prodrug siRNA
Cytoplasmic
thioesterase
Figure 9. siRNNs (left) with “masking” modifications, that turn into the “naked” siRNA 
(right) after entering the cell. Reprinted from Meade et al., Nature Biotechnology, 2014 
with a kind permission from Springer Nature
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For the successful RISC formation, it is important to maintain the siRNA double-
stranded helix shape, that severely restrict the possible modifications. The siRNN 
is a result of the several inventions in the nucleic acid chemistry that aimed to 
increase the success of in vivo drug delivery. For example, 2’- sugar modifications 
such as 2’-O-Me and 2’-F are some of the most commonly used modifications in 
clinical trials. They successfully mimic the original 2’-OH, but also help to escape 
the destruction by nucleases, to evade activation of the Toll-like receptors (TLRs) 
and induction of the interferon response in the blood. 166,175 It has also been shown 
that the 2’-sugar hydroxy group replaced by O-Me helps to avoid immune recogni-
tion by TLR7/8 without suppressing the capacity of RNAi. 166 
Further, the overall reduction of the siRNA charge promotes its stability and chances 
to be delivered to the target cell. Therefore, the negatively charged phosphodiester 
backbone of a naked siRNA should also be masked. For this reason, phosphoro-
thioate, morpholino, phosphotriester and peptide nucleic acid modifications were 
proposed. 125 In our studies the phosphodiester backbone is modified with a neutral 
bioreversible phosphotriester group that is also used as a link to the delivery peptide. 
The modified drugs represent siRNAs that are conjugated to a TAT-peptide via an 
S-acyl-2-thioethyl (SATE) group that enables the delivery of siRNN into the cell. 
A TAT protein transduction domain, also known as a cell penetrating peptide, was 
suggested to cross the lipid bilayer of the cell membrane via endocytosis. 176 Upon 
entering the cytoplasm, the phosphotriester bonds are processed by cytoplasmic 
enzymes, named thioesterases which cleave the thioester bond within the SATE 
group. As the thioesterases are present only in the cytoplasm, the “de-masking” 
of the siRNN molecule takes place only inside the cell. The cleavage results in 
a two-step rearrangement process of the modified phosphotriester siRNN into a 
naked siRNA with a negatively charged phosphodiester backbone. Further, the 
siRNA is loaded into RISC together with Ago2, and the loading is followed by a 
targeted cleavage of Plk1 mRNA (Figure 10). 
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Figure 10. Graphical description of Plk1 siRNN mode of action upon treatment. 
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2 AIMS
The overall aim of the present thesis was to study the potential of Plk1 as a treat-
ment target for pediatric acute leukemia using small molecule inhibitors and novel 
RNAi-based drugs. 
Specific aims:
• To map off target proteins that are bound to the small molecule Plk1 inhibitors 
in order to shed light on the mechanism of adverse effects in patients treated 
with these drugs; 
• To investigate the expression of the Plk family members in primary cells from 
pediatric ALL patients and healthy donors;
• To target Plk1 in leukemic blasts isolated from the PB and BM samples from 
T-cell ALL and B-cell ALL patients using siRNNs and a small molecule Plk1 
inhibitor volasertib;
• To analyze the toxicity of siRNNs towards primary cells from healthy donors.
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3 RESEARCH APPROACH AND MAIN 
FINDINGS
3.1 Paper I. Investigating the target landscape of Plk1 
small molecule inhibitors using thermal proteome 
profiling
In this work, we applied a strategy to study the effect of Plk1 small molecule inhibi-
tors on the multiple proteins based on the thermal stability of each protein. We used 
the results of thermal proteome profiling to get an insight into the mechanisms of 
the adverse effects found in patients treated in clinical trials.
Unpredicted adverse effects in patients enrolled in clinical trials on novel thera-
pies is an important issue to be solved. Before a small molecule inhibitor reaches 
patients, it undergoes multiple preclinical studies in vitro and in vivo. During the 
drug development process the attention is paid mostly to confirm the target bind-
ing. Even preclinical studies on animals do not fully reveal the potential adverse 
effects that will occur in human patients. 55,177 Therefore, there is a need to inves-
tigate the off-targets of a drug in order to predict and potentially avoid adverse 
effects in the future. 
Several methods have been developed to understand the drug-protein and protein-
protein interactions under the different conditions. Multi-channel fluorescence 
microscopy was suggested to identify these interactions as a “live in-cell  western 
blotting”. 55 However, this method has its limitations, such as the necessity of 
blocking procedure or incubation with primary and secondary antibodies that 
require optimization due to potential issues with obtaining a strong and valid 
signal. Förster (also named fluorescence) resonance energy transfer (FRET) is 
another method used in studying the protein-protein interactions. FRET is used for 
screening of the small molecules binding to a one particular protein. 178 While the 
method requires designing of a specific biosensor for a studied protein, it limits 
the unbiased identification of previously unknown targets. 179 
We decided to use a different approach. It is known, that ligand-protein binding 
results in a conformational change followed by a shift in the protein melting tem-
perature. The thermal shift – when detected – can potentially confirm a presence 
of a drug-protein bond (Figure 11). 
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Figure 11. Concept of the protein thermal shift upon drug treatment
Cellular thermal shift assay (CETSA) is an affinity-based strategy that is used to 
evaluate the thermal stability of a drug-protein complex. 180 The method is applied 
for unbiased study of direct or downstream interactions in a complex cellular 
environ ment. The thermal shift can be detected by western blotting (WB) or liquid 
chromatography – mass spectrometry (LC-MS). 
We used WB as a first step to confirm that Plk1 small molecule inhibitor volas-
ertib bound to Plk1. We treated several cell lines to investigate if a melting shift 
is cell dependent. For the CETSA-WB the cells were treated, harvested, and lysed 
via triple snap freezing-thawing followed by centrifugation to separate cell debris 
from the cell lysate (Figure 12). 181 We confirmed that volasertib binds to Plk1 
in different cancer cell lines by observing a thermal shift at 47 °C. Notably, this 
method relies on the availability of a specific high-quality monoclonal antibody 
against Plk1. 
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Figure 12. Flow-chart of the experiments conducted for the paper I 
Thermal proteome profiling (TPP) is a development of CETSA when quantita-
tive MS is used to identify binding between small molecule inhibitors and target/
off-target proteins. 52,182 The use of this method led to discovery of the unexpected 
interactions by clustering the protein kinases in different groups according to the 
promiscuity to a specific compound. We investigated the proteomic profile of 
leukemic cells after treatment with three different Plk1 inhibitors namely BI2536, 
volasertib and NMS-1286937 by running Tandem Mass Tag 10Plex (TMT10Plex) 
for LC-MS/MS. TMT10plex is one of the variants of peptides labelling with 10 
isotopic mass tags with further peptide separation during LC, fragmentation and 
quantification in MS/MS mode. For this experiment we treated Jurkat cells with 
20 µM of the drugs. It is known that a high concentration of the drug decreases its 
selectivity. However, a micromolar-range dose was used to maximize the coverage 
of the proteins affected by the drug. Moreover, in preclinical mouse studies it was 
shown that treatment with 35 mg/kg of volasertib led to a drug accumulation in 
tissues with the highest concentration 32 µM at 8 h after treatment, compared to 
plasma concentration up to 7 µM after 1 h. 140 At the last time-point measurement, 
tumor and plasma concentration corresponded 4 µM and 8 nM respectively. This 
data supports the choice of 20 µM drugs concentration for TPP.
First, our results showed that BI2536 and NMS-1286937 also bind to Plk1 and 
change its melting temperature in the treated cells, compared to dimethyl sulfoxide 
(DMSO)-treated controls. Second, we obtained a list with several thousands of 
proteins that were detected by MS upon treatment. These hits were affected either 
by direct interaction with the drug or by downstream effect. We sorted the hits 
according to the non-parametric adjusted p-value for the further validation experi-
ments, aiming to identify the relevant off-targets not compromising on specific-
ity. 183 We compared the hit lists of the drugs and found no overlaps between three 
of them. Therefore, we decided to analyze the overlaps between the pairs “BI2536 
– volasertib”, “volasertib – NMS-1286937” and “BI2536 – NMS-1286937” using 
publicly available databases, such as STRING and ENRICHR. In the STRING 
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database, the protein-protein interactions of the whole genome can be evaluated, 
while ENRICHR is a gene enrichment analysis tool. The gene enrichment analysis 
sorted the hits into functional groups to see the what genes and pathways were 
affected by treatment. We selected the proteins for the future validation based on 
the known interactions and described protein functions.
The results showed that the drugs disturbed several functional pathways. For 
example, both volasertib and NMS-1286937 affected the key proteins in fertility 
and immune system regulation (KIF1BP), histones and chromatin remodeling 
(HP1BP3) lipid metabolism (LSS), or heme biosynthesis (PPOX). Furthermore, 
BI2536 and volasertib overlapped on the effect on enzymes involved in prosta-
glandin (PTGR2) or phosphatidyl-inositol metabolism (PIP4K2C), cell prolifera-
tion (FNTB), fertility regulation (PPT1) and RNA processing (PHF5A, NUDT1). 
Notably, not all changes in thermal profiles occur due to a direct effect of inhibitors. 
Thermal shifts can also occur as a downstream effect after Plk1 destabilization. 
For example, we can assume that this might be the case for MZT1 that can be 
affected as a downstream target of Plk1. 
Febrile neutropenia and sepsis were among the most common reported adverse 
reactions in patients treated in the phase I-III clinical trials with Plk1 inhibitors 
and volasertib in particular (Figure 7). 148,184,185 Therefore, we decided to investi-
gate which proteins from our hit list could potentially contribute to the disruption 
of the immune function. 
One of the proteins that was affected by both BI2536 and volasertib was PTGR2. 
It is an enzyme, that is involved in prostaglandin E2 (PGE2) metabolism. PGE2 
is synthesized from arachidonic acid by enzymatic activity of cyclooxygenases 
1 and 2 (COX1 and COX2). PGE2 is known for its crucial role in the inflamma-
tory response by modulating cytokine production, and was shown to contribute 
to sepsis development. 186,187 We hypothesized that in case of PTGR2 inhibition, 
the reversible mechanism of PGE2 metabolism will lead to an increase of PGE2 
concentration and potentially will contribute to a high incidence of sepsis and 
bacterial infection in volasertib-treated patients.
Therefore, in order to validate the hypothesis that PTGR2 is a true off-target of 
volasertib, one of the future steps is to run LC-MS/MS to quantitatively compare 
the final amount of the proteins between DMSO-, volasertib- and NMS-1286937-
treated cells at clinically relevant concentrations (25 and 500 nM). The “absorption, 
distribution, metabolism and excretion” (ADME) study on volasertib revealed that 
the maximal measured concentration of the drug in plasma was 926 nM with 17.8% 
coefficient of variation. 188 We experimentally identified 25 nM of volasertib as a 
minimal toxic dose for Jurkat at 48h timepoint. Therefore, performing the valida-
tion experiments on PTGR2 with volasertib at 25 nM and 500 nM would render 
clinically relevant results. 
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Important consideration is that Jurkat is one of the most widely used cell lines for in 
vitro studies in ALL. However, as any other result from the cell lines, our data has 
to be carefully extrapolated to a clinical setting. Additional experiments on healthy 
PBMCs should be done to see the effect of the drugs on the immune response. 
3.2 Papers II and III. Targeting primary cells from 
pediatric T-cell and B-cell ALL patients with 
RNAi- prodrugs
The field of modified siRNAs is quickly expanding due to their potential to target 
“undruggable diseases” by modulating the mRNA expression, such as rare syn-
dromes or “single gene disorders”. Despite that cancer is a complex multifacto-
rial disease, siRNA-based therapeutics can be effectively used in targeting a gene 
that is important for cancer cell proliferation or survival. As Plk1 is known as an 
attractive anti-cancer target, crucial for cancer cell division, we decided to use 
RNAi against Plk1 mRNA as a selective therapy approach. 
3.2.1.1 Ethical considerations of primary cells use
Research that involves material from patients, especially children, always requires 
additional care. In papers II and III we used PB samples and BM aspirates, col-
lected from pediatric ALL patients as a part of diagnostic process before the treat-
ment. Therefore, the collection of patient samples for our projects did not require 
additional intervention or discomfort for the sick children. 
One of the recommendations from reviewers during the publication process was to 
include more patients in the study. As shown in the Figure 2A/2B and according 
to the NOPHO statistics, every year approximately 200 children get ALL. 26 
Therefore, there are limitations on availability of new samples from pediatric 
patients. 
As healthy controls, we used peripheral mononuclear blood cells (PBMC) from 
adult healthy donors. Some reviewers suggested to avoid comparing Plk family 
mRNA expression between cells from patients with pediatric ALL and healthy 
adults due to a potential age-dependent difference in mRNA expression. However, 
the enrollment of healthy children in the studies and exposing them to a painful 
procedure has to be ethically clarified and approved. Moreover, different studies also 
used PBMCs from adult healthy volunteers to study pediatric leukemia. 20,136,189,190 
We checked the publicly available databases for the Plk family expression to 
compare with our results, and found correlation in regard to Plk1, Plk2 and Plk4, 
however, not Plk3 expression. In conclusion, we suggested our data to be reliable 
for publication.
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3.2.1.2 Experimental flow
First, we evaluated the mRNA expression of the Plk family in cell lines, patient 
samples and healthy PBMCs (Figure 13). Our data supported the previous reports 
about a high expression of Plk1 in cancer cells, including cell lines and primary 
patient cells. We also observed a significantly higher expression of Plk4 in tumor 
cells compared to healthy cells, that aligned with the data about the potential role 
of Plk4 as an oncogene. 
Figure 13. Polo like kinases family expression (Plk1-Plk4) summary from the papers II 
and III
In the paper III we also performed a comparative analysis of Plk1-Plk4 mRNA 
expression in sorted healthy CD19+ B-cells and B-cell ALL primary patient cells 
derived from the PB. The data was obtained from the publicly available database 
R2: Genomics analysis and visualization platform. The analysis showed that the 
expression pattern of Plk1 and Plk4 followed the same trend as found in our obser-
vations of high Plk1 and Plk4 mRNA expression in primary cells. However, the 
expression of Plk3 in the dataset was higher in B-cell ALL samples, in contrast 
to our data. One explanation is that the expression pattern of Plk3 varied due to 
its involvement in the stress response. As seen on the Figure 6, the level of Plk1 
mRNA expression from the publicly available databases was shown to be higher 
in a BM compared to PB. BM in a healthy individual is a special environment 
filled with different types of rapidly dividing cells, therefore a high expression of 
Plk1 was observed.
31
The identification of a high expression of Plk1 in the patient cells indicated that 
Plk1 was a promising target to knockdown with siRNNs. However, handling of 
the primary cells usually requires additional stimulation with growth factors or 
interleukins (Figure 14). In the paper II we combined anti-biotin MACSiBead 
Particles with biotinylated human CD2/CD3/CD28 antibodies with an addition of 
IL2 (Figure 14). Loading of the particles with the antibodies is required to mimic 
the antigen-presenting cells (APCs) and to activate resting T-cells. Anti-CD3 binds 
to CD3 receptor and activates CD3-TCR complex. The manufacturer recommends 
using MACSiBead Particles to activate healthy T-cells, however, we successfully 
applied similar strategy for primary cancer cells. In the paper III we activated the 
B-cells with CD40Ligand (CD40L) and a mix of cytokines IL2, IL4 and IL7. CD40 
receptor is expressed on B-cells in ALL, and CD40L mimics a T-cell depend-
ent activation of naive B-cells and helps to stimulate the B-cell to enter the cell 
cycle. 191,192 IL2 and IL7 increase B-cell proliferation and IL7 alone is important 
for in vivo B-cell maturation. 193 After or simultaneously with the activation, we 
treated the primary cells with siRNNs.
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Figure 14. Primary T-cell activation protocol of the cells, applied in the paper II.
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RNAi-based therapies are relatively novel, therefore, the experiments on siRNA-
based drugs have to fulfill certain criteria in order to gain technically sound 
results. 162 For example, one of the initial steps in the Plk1 siRNN development 
(prior to the start of the studies for the papers II and III) included evaluation of six 
different Plk1-targeting siRNA sequences. 167 Out of the six, two sequences induced 
the highest percentage of G2 arrest in U2OS cells, what was repeated in our lab 
with siRNA for the paper III. Finally, one sequence was chosen for future work. 
A transfection reagent (i.e. lipofectamin) is necessary for siRNA to be transfected 
inside the cell due to its large size and negative charge. In contrast, the modifica-
tions applied to siRNN such as TAT-peptide, phosphotriester links and 2’- modi-
fications (2’-F and 2’-O-Me) allow the intracellular self-delivery via endocytosis. 
In our experiments, we used si-negative sequence as a control for siRNA and 
short interfering Luciferase (Luc siRNN) sequence as a control for Plk1 siRNN. 
One of the issues that is still has to be solved is a relative toxicity of Luc siRNN 
towards patient cells. 
To evaluate and validate the efficiency of transfection with siRNA and treatment 
with siRNN, we used methods such as real time – quantitative polymerase chain 
reaction (RT-qPCR), WB, cell cycle analysis, apoptosis evaluation by staining 
with Annexin V (AxV)/propidium iodide (PI) staining, and cell viability assay. 
Treatment of the cell lines and successful activation of the primary T-ALL cells 
(paper II) allowed to perform at least two or three independent experiments with 
siRNNs and obtain the results from all the above-mentioned methods. However, 
this was not possible in the paper III due to a low number of primary cells in each 
patient sample. Overall, we analyzed the siRNNs in the cell lines and primary 
patient cells and succeeded to obtain statistically significant Plk1 knockdown.
Simultaneously, we assessed the specificity of siRNNs by measuring a rela-
tive mRNA expression of Plk2, Plk3 and Plk4. As a functional assay, we used 
RT-qPCR to show an increase in Mediator of DNA damage checkpoint 1 (MDC1), 
a marker of dsDNA breaks (paper III). The group of histones H2 is involved in a 
post-translational modification of chromatin and H2 phosphorylation is a DNA 
 damage marker. MDC1 is recruited by ataxia telangiectasia-mutated (ATM) kinase 
to phosphorylated gamma H2AX (pH2AX), and in turn, MDC1 recruits ATM 
kinase together with multiple proteins to the break point and form a so-called foci, 
what is required for the further checkpoint activation, damage repair or histone 
ubiquitination. 194,195
In the experiments in the papers II and III we had to ensure the decrease in Plk1 
protein level and show that Plk1 mRNA knockdown induced a programmed cell 
death – apoptosis in the cancer cells. In our studies, we used WB to detect apop-
tosis markers such as cleaved Poly (ADP ribose) polymerase (PARP) and G2/M 
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arrest marker phospho-histone H3 (pH3). PARP cleavage occurs in case of a vast 
DNA damage and apoptosis, that is catalyzed by caspase 3. 196 Phosphorylation of 
the histone H3 (pH3) on the Ser10 residue is another G2/M arrest and apoptosis 
marker. 197 Therefore, the expression of these proteins supported the data that Plk1 
mRNA cleavage results in G2/M arrest and apoptosis. It has also been shown that 
Plk1-depleted cells after dsDNA damage are unable to continue mitotic progres-
sion, therefore we evaluated the levels of pH2AX using WB to confirm the results 
from RT-qPCR on DNA breaks induction upon treatment with Plk1 siRNN. 
Cell cycle analysis with PI in the primary cells of T-cell ALL patients and PBMCs 
from the healthy donors (paper II) was used to show the redistribution of the cell 
cycle phases (G1, S and G2/M) after stimulation. In the paper III, we confirmed the 
cell cycle arrest in G2/M after treatment with two different Plk1 siRNA sequences 
in U2OS cell line and G2/M arrest after Plk1 siRNN treatment in 697 and SupB15 
cell lines. Due to technical limitations, we could not run the cell cycle analysis on 
the patient cells, however, high Plk1 mRNA expression in unstimulated samples 
gave an indication that cells were viable and entered the cell cycle after thawing. 
AxV/PI staining is used to measure the number of apoptotic and necrotic cells 
using flow cytometry. AxV staining detects the presence of phosphatidylserine 
on the cell surface and indicates the disrupted permeability of the cell membrane. 
In case of severe damage, PI can cross the cell membrane and stain the nucleus, 
indicating late apoptosis and necrosis of the cells. In paper II we showed that Plk1 
siRNN increases the number of AxV-positive population in primary cells, while 
in paper III we were able to use this method only on cancer cell lines. 
Overall, our data provides basis for the future in vivo experiments with Plk1 siRNN. 
Meade et al. showed that TAT-siRNN did not induce IFNα production in PBMCs, 
while in vivo delivery of GalNAc-siRNN induced a strong RNAi response. 167 The 
question of side effects in case of in vivo Plk1 mRNA knockdown is important to 
consider due to Plk1 functions and the potential as an anticancer target, therefore 
Raab et al. created an in vivo model with doxycycline – induced shRNA Plk1 
knockdown. 198 It was shown that Plk1 silencing did not lead to a BM suppression, 
keeping normal levels of WBCs and erythrocytes compared to the wild type mice. 
The only difference was a decreased ferritin level. Moreover, silenced Plk1 did 
not affect the growth of primary healthy cells such as fibroblasts, keratinocytes 
and endothelial cells. These data indicated that Plk1 silencing leads to the tumor-
selective apoptosis and does not affect normal cells. 
Therefore, if you ask, “Is there a clinical future in Plk1 siRNNs?”, I will say “Yes”. 
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4 FUTURE PERSPECTIVES
In 2015 the European Society of Pediatric Oncology (SIOPE), together with several 
international collaborators, developed and published a strategy to “cure more and 
cure better childhood cancer by 2030” (Figure 15). 199 From this perspective, the 
current thesis contributed to two strategic steps. 
Figure 15. EU pediatric cancer mission, proposal from European Society of Paediatric 
Oncology (SIOPE). Adaptation of the framework presented by Mariana Mazzucato in 
“Mission – oriented research & innovation in the European Union” 200
The first step is to develop a more effective and less toxic treatment. Despite that 
small molecule inhibitors have already been used in clinics, there is still a great 
need for other therapies in the cancer management including RNAi therapeutics. 
The delivery methods of siRNA-based drugs are extensively improving, allowing 
specific and non-immunogenic treatment of blood malignancies. Another thera-
peutic challenge is related to resistant patients. However, it is still unclear if the 
level of Plk1 expression influences tumor resistance and if the primary/secondary 
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resistance mechanism will affect the intracellular delivery of siRNA-based drugs. 
Therefore, more studies are needed to evaluate the potential of using RNAi-based 
therapies in resistant/relapsed patients. 
The second step aims to reduce long-term consequences from toxicities during 
and after the treatment. Paper I showed that one drug alone can change the whole 
landscape of the cellular processes in the body, not always for the benefit of the 
patient. Thus, more studies on the anticancer drug off-targets will help to predict 
potential complications and likely help to switch to the more efficient protocols. 
As for now, Plk1 is a promising target for patients with different types of cancers 
and leukemia in particular. Analysis and comparison of the adverse reactions 
that occur after treatment with small molecule inhibitors and novel RNAi-based 
 therapies, such as givosiran, suggest that siRNA-based drugs can potentially 
exhibit lower toxicity. However, in case of Plk1 siRNN, in vivo studies and com-
putational modelling are needed to predict the potential effect of treatment and 
possible combinations to ensure synthetic lethality in cancer cells. 
It is interesting to observe how scientific developments change the treatment 
approaches and expand the field of personalized medicine. Doctors have to keep 
in mind that every day we are getting closer to the opportunity to treat each unique 
patient individually. The clonal variability of tumors requires treatment with sev-
eral drugs with different mode of action. The development of novel combination 
protocols i.e. with monoclonal antibodies, with revised doses of chemotherapeu-
tical drugs and with targeted oligonucleotides-based therapies is one of the tasks 
of personalized medicine. This approach can potentially decrease the duration 
of treatment, reduce severity of the adverse reactions and improve outcomes in 
patients. The increased quantity and quality of data from genome-wide associa-
tion studies and development of artificial intelligence might also contribute to a 
better treatment of cancer patients.
Another crucial point in the future considerations is that RNAi therapies require 
not only optimizing the intracellular delivery methods, but also set a challenge 
of manufacturing processes of the large amounts of modified siRNAs, quality 
controls and delivery to a patient. This field requires a collaborative approach in 
terms of discovery, evaluation, and development of the infrastructure to produce 
the drug and treat a patient.
In conclusion, the present thesis contributes to the fight against a pediatric cancer 
specifically by adding a brick of information to prevent long-term consequences 
of treatment in patients with acute leukemia and introducing innovative effective 
and less toxic treatments. 
36
5 POPULAR SCIENCE SUMMARY
Leukemia is a form of blood cancer that very often affects children. Currently, to 
treat one type of leukemia – acute lymphoblastic leukemia – doctors use a com-
bination of different chemotherapeutic drugs that are toxic to cancer cells and the 
normal cells of the body. This toxicity leads to severe side effects during the treat-
ment and many years after the completion of the therapy. This issue is especially 
important for children that survive cancer, because in the long-term perspective 
they have an increased risk of secondary tumors, infertility, mental and/or heart 
problems. Therefore, there is a permanent search for new treatments that are both 
efficient against cancer and have less side effects. 
During the recent years it became clear that RNA has many more functions than 
just being a transcript for a protein synthesis. One of the approaches that our bod-
ies developed evolutionary to silence the alien RNA, for example from viruses, 
is called RNA interference (RNAi). In the light of developing gene therapies, it 
became evident that specific messenger RNAs (mRNA) can be used as targets to 
silence the translation of the proteins important for the cancer cell proliferation 
and growth. RNAi happens inside every cell, normal and cancer, and is induced 
by both endogenous and alien RNA. Once inside the cell, special enzymes can cut 
the alien RNA into short interfering (si)RNA, that connects to specific proteins to 
form a so-called RNA-induced silencing complex, or RISC. This complex induces 
a cascade of events that result in elimination of a protein-coding mRNA. Lack or 
absence of the protein leads to the lack of function. Scientists use this method not 
only for learning and understanding the function of different genes and proteins, 
but also to treat diseases, including cancer. 
Plk1 is an important protein that helps any cell to divide. Without Plk1 cancer 
cells cannot grow and die via a specific cell death process called apoptosis. Thus, 
Plk1 was identified as a good target for anticancer treatment, and pharmaceutical 
companies have developed several small molecule drugs that block the function of 
Plk1. Unfortunately, the tested drugs have induced many side effects in patients, 
and in one of our studies we investigated the potential off-target proteins of these 
drugs and which of the proteins could be responsible for the unfavorable outcomes 
in clinical trials. 
We also analyzed a modified siRNA molecule named siRNN that targets Plk1 and 
showed that leukemic cells that were taken from the patients and put in culture 
die after our treatment. Moreover, our modified drug did not cause any changes 
in synthesis of other proteins that belong to the same family as Plk1 and proved 
to be less toxic towards normal blood cells compared to small molecule drugs. 
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Therefore, Plk1 siRNN can be further investigated and can be implemented in the 
future for acute leukemia treatment. 
In a nutshell, this thesis has improved the understanding of side effects caused by 
the small molecule inhibitors against Plk1 and introduced a novel drug that is more 
selective and might cause less side effects in children with ALL. Future studies 
will help to understand better what group of patients will benefit the most from 
the proposed treatment and what combinations of drugs should be used. 
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